linjc16/ctgov huggingface dataset:
Evaluation of Endovenous Sclerotherapy for Treatment of Varicose Veins

Study Overview
=================
Brief Summary
-----------------
The overall objective will be to evaluate clinical predictors of outcomes in patients who undergo endovenous sclerotherapy for the treatment of varicose veins.

Detailed Description
-----------------
A prospective cohort study of patients who undergo endovenous sclerotherapy over 2 years. There are no deviations in usual clinical assessment and care of patients seeking varicose vein treatment. The purpose of this protocol is only to collect clinical and biomarker information related to this standard treatment.

Official Title
-----------------
Evaluation of Clinical Characteristics of Endovenous Sclerotherapy of Varicose Veins

Conditions
-----------------
Varicose Veins

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of varicose veins Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endovenous Sclerotherapy<br>For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of obliteratin (total or partial) of injected varicosity. |  | assessment will be at 1, 12, and 26 weeks. | 
| Improvement in venous stasis symptoms. |  | assessment will be at 1, 12, and 26 weeks | 
| Change in quality of life. |  | assessment will be at 1, 12, and 26 weeks | 
| Associations between clinical outcomes and biomarkers. |  | assessment will be at 1, 12, and 26 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of varicosities. |  | assessment will be at 1, 12, and 26 weeks | 
| Adverse events reported following procedure. |  | assessment will be at 1, 12, and 26 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Varicose Veins, Superficial Thrombophlebitis, Deep Vein Thrombosis, Ulceration, leg pain, leg swelling
Comparison of Albuterol for Status Asthmaticus

Study Overview
=================
Brief Summary
-----------------
This study is designed to compare the length of continuous albuterol administration between two different albuterol formulations, BAC containing albuterol versus preservative free albuterol.

Detailed Description
-----------------
The primary objective of this study is to compare the length of continuous albuterol administration between patients receiving BAC containing albuterol versus preservative free albuterol. Secondary objectives include comparison of therapy escalation, asthma scores, forced expiratory volume in one second (FEV1) at discharge, length of hospital stay, and cost.

Official Title
-----------------
Comparison of Benzalkonium Chloride Containing Albuterol Versus Preservative Free Albuterol for the Treatment of Status Asthmaticus

Conditions
-----------------
Status Asthmaticus

Intervention / Treatment
-----------------
* Drug: preservative free albuterol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will be included in the study if they are admitted to the 5th floor of Norton Children's Hospital for the treatment of an acute asthma exacerbation, initiated on continuous albuterol inhalation therapy, and are between 5 and 17 years of age. Exclusion Criteria: Patients will be excluded from the study if they are transferred from the 5th floor to the Pediatric Intensive Care Unit (PICU), admitted for any indication other than acute asthma exacerbation, or removed from the inpatient asthma protocol for any given reason.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Benzalkonium chloride (BAC) Albuterol<br>This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients. | |
| Experimental: Preservative Free Albuterol<br>This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation. | Drug: preservative free albuterol<br>* Preservative free albuterol for nebulization<br>* Other names: 0487-9901-30;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Albuterol Administration | Length of continuous albuterol administration between patients receiving BAC containing albuterol versus preservative free albuterol during hospital admission for status asthmaticus | Hours until discontinuation of therapy, an average of 72 hours |
Family Study of Lymphoproliferative Disorders

Study Overview
=================
Brief Summary
-----------------
Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development of these cancers.

Official Title
-----------------
Genetic Epidemiology of Lymphoproliferative Disorders

Conditions
-----------------
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Monoclonal B-Cell Lymphocytosis, Multiple Myeloma

Participation Criteria
=================
Eligibility Criteria
-----------------
At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk of blood or lymphoma |  | Ongoing |
System Accuracy of the Blood Glucose Monitor for Personal Use BG-709b

Study Overview
=================
Brief Summary
-----------------
This study assesses the system accuracy a blood glucose monitoring systems pursuant to ISO 15197

Detailed Description
-----------------
This study assesses the system accuracy the blood glucose monitoring systems for personal use BG-709b as outlined in DIN EN ISO 15197:2015.

Official Title
-----------------
Evaluierung Der Systemgenauigkeit Des BG-709b Blood Glucose Monitoring Systems Der Firma Sejoy gemäß DIN EN ISO 15197:2015

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Diagnostic Test: blood glucose measurement, blood glucose monitor for personal use
* Diagnostic Test: blood glucose measurement, laboratory reference device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients with clinical indication for blood glucose testing Signed form of consent Minimum age of 18 years Subjects are legally competent and capable to understand character, meaning and consequences of the study Exclusion Criteria: Pregnancy or lactation Severe acute disease (at study physician's discretion) Acute or chronic diseases with inherent risk of aggravation by the procedure (at study physician's discretion) Current constitution that does not allow participating in the study (e.g. hematocrit out of the devices's specifications, medication known to influence blood glucose measurements; Appendix A of ISO 15197) Being unable to give informed consent Age younger than 18 years Legally incompetent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subject glucometer measurement<br> | Diagnostic Test: blood glucose measurement, blood glucose monitor for personal use<br>* measurement of the blood glucose concentration using the blood glucose monitor for personal use (BG-709b)<br>Diagnostic Test: blood glucose measurement, laboratory reference device<br>* measurement of the blood glucose concentration using a laboratory reference device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of system accuracy based on DIN EN ISO 15197 | Assessment of the analytical measurement performance of the blood glucose monitor based on procedures defined in DIN EN ISO 15197 | day 1 |
The Role of Splinting in Fingertip Injuries

Study Overview
=================
Brief Summary
-----------------
This study is attempting to understand whether or not splinting after a fingertip injury improves recovery.

Official Title
-----------------
The Role of Splinting in Fingertip Injuries

Conditions
-----------------
Injury Distal to Flexor and Extensor Tendon Insertions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: injury distal to flexor and extensor tendon insertions crush, avulsion, amputation, or penetrating injury to the fingertip isolated injury, within two weeks Exclusion Criteria: operative fixation required unable to participate in rehab

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Splint | |
| 2<br>No Splint | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DASH questionnaire, Grip strength, and Range of Motion |  | 1 month |
Characterization of Slow Coronary Flow

Study Overview
=================
Brief Summary
-----------------
Description of the phenomena Slow Coronary Flow (SCF), according to the data that has been collected from patients hospitalized with specific criteria. Clinical follow-up of these patients to determine whether they suffered from any cardial or psychological disorders that might be a result of SCF.

Conditions
-----------------
Cardiovascular Abnormalities, Vascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: anginal pain laboratory markers pathological ECG for ischemia Exclusion Criteria: obstructed coronary artery during catheterization very narrow coronary artery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Slow Coronary Flow<br>Patients who were hospitalized with anginal pain and with laboratory markers or pathological ECG for ischemia. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of characteristics of slow coronary flow from approximately 90 patient records | Characteristics of slow coronary flow will be collected from approximately 90 patient medical records and will analyzed to find the common variables. This analysis will show whether there is any statistical significance to these characteristics. | Six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Slow Coronary Flow
AZD6765 for Treatment Resistant Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.

Official Title
-----------------
A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Drug: AZD6765


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Depression Inadequate response to an adequate course of antidepressants Exclusion Criteria: Psychiatric disorder other than depression Pregnancy or lactation Current diagnosis of cancer

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AZD6765|intravenous infusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary objective is to determine whether an antidepressant effect can be achieved in patients with Treatment Resistant Depression determined by a change from baseline in the MADRS total score. |  | Change from Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary objective is to assess the safety and tolerability of AZD6765 as assessed by vital signs, physical examination, clinical laboratory evaluations, ECG's and incidence of adverse events. |  | each visit; change from baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Long-term depression
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas

Study Overview
=================
Brief Summary
-----------------
The primary aim of the study is to assess mortality and cardiovascular events potentially linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol values following the 1-mg overnight dexamethasone test.

Detailed Description
-----------------
The NAPACA Outcome Study is part of the ENSAT Registry (https://registry.ensat.org/)

Official Title
-----------------
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas - Substudy of the ENSAT (European Network for the Study of Adrenal Tumor) Registry

Conditions
-----------------
Adrenal Incidentaloma

Intervention / Treatment
-----------------
* Diagnostic Test: 1mg Dexamethasone test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥18 years adrenal incidentaloma (≥ 1cm) detected by cross-sectional imaging between January 1, 1996 and December 31, 2015 imaging characteristics suggestive for an adrenal adenoma or excluded malignancy by follow-up imaging availability of a 1 mg dexamethasone test result follow-up data on living status and occurrence of cardiovascular events follow-up duration of at least 36 months. Exclusion Criteria: proven pheochromocytoma, primary hyperaldosteronism or adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome clinical features suggestive for overt Cushing's syndrome; urinary free cortisol (UFC) ≥ 2-fold higher than the upper limit of normal of the local assay any active malignancy (including adrenocortical cancer) at the time of primary diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: 1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | death | From date of primary diagnosis of the adrenal incidentaloma until December 31, 2018 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular morbidity | Cardiovascular (CV) events (myocardial infarction, percutaneous coronary intervention, coronary bypass, stroke, deep vein thrombosis, and pulmonary embolism) | From date of primary diagnosis of the adrenal incidentaloma until December 31, 2018 |
Glucose Monitor Accuracy Investigation (Ⅰ)

Study Overview
=================
Brief Summary
-----------------
According to Section 7.3 and Section 7.4, ISO 15197(2003), it adopts the whole blood of fingertips and vein as samples to evaluate the accuracy of portable BGM.

Detailed Description
-----------------
The clinical medical technologists collected blood samples from 308 volunteers including 87 diabetics and 221 healthy people. The range of the blood glucose concentration was from 41.2mg/dL to 521mg/dL. The result of clinic evaluation shows that the accuracy of BGM matches the requirement of ISO15197(2003).

Official Title
-----------------
Glucose Monitor Accuracy Investigation (Ⅰ)

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: volunteers with diabetes and non-diabetes Exclusion Criteria: hypertension,fever,AIDS,hemophilia

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glucose |  | 10 min |
The Influence of an Intervention Program on Altering Health Behavioral Patterns Among IDF's Staff

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to determine the effectiveness of a general intervention that includes encouragement of physical activity and healthy living habits of officers and permanent staff in the IDF

Conditions
-----------------
Physical Fitness Habits, Balanced Nutrition, Weight Reduction, Smoking Cessation, Reduction of Stress

Intervention / Treatment
-----------------
* Behavioral: Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IDF'S staff member Age >26 One or more risk factor Exclusion Criteria: Cardio vascular condition Respiratory disease Other healthy conditions according to the physician's decision

Ages Eligible for Study
-----------------
Minimum Age: 26 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Lifestyle counseling<br> | Behavioral: Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff<br>* the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| physical fitness habits weight reduction balanced nutrition |  | one year |
High Intensity Cycling Before SCUBA Diving Reduces Post-decompression Microparticle Production and Neutrophil Activation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the impact of high intensity,anaerobic exercise, in the form of cycling, on SCUBA diving. Outcomes are determined by the quantification and subtype of circulating microparticles, complete blood counts, and the quantification of venous gas emboli, measured via transthoracic echocardiography, in the cardiac cavities.

Official Title
-----------------
High Intensity Cycling Before SCUBA Diving Reduces Post-decompression Microparticle Production and Neutrophil Activation

Conditions
-----------------
Decompression Sickness, SCUBA Diving

Intervention / Treatment
-----------------
* Other: High intensity exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Experienced divers (> 250 logged dives) Male Physician clearance to dive Exclusion Criteria: Prior incidence of decompression sickness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High intensity exercise<br>A dive to 18 meters sea water for a duration of 41 minutes preceded by high intensity cycling | Other: High intensity exercise<br>* Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline values of number of circulating microparticles per microliter of blood |  | Prior to exercise, prior to diving, 15 and 120 minutes after surfacing | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SCUBA diving, exercise,, microparticles, neutrophil activation,, high intensity exercise